Vol 9, No 3 (June 22, 2020): Chinese Clinical Oncology (Neoadjuvant/Adjuvant Treatment for Early Breast Cancer)

Editorial on Neoadjuvant/adjuvant Treatment for Early Breast Cancer1

Focused issue “Neoadjuvant/adjuvant treatment for early breast cancer”
Yutaka Yamamoto, Takayuki Ueno

Review Article on Neoadjuvant/adjuvant Treatment for Early Breast Cancer1

Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer
Takayuki Iwamoto, Yukiko Kajiwara, Yidan Zhu, Shigemichi Iha
Prospect of immunotherapy in neoadjuvant/adjuvant treatment for early breast cancer
Minoru Miyashita, Takanori Ishida
The history, present situation, and future directions of neoadjuvant chemotherapy for HER2-negative breast cancer
Masahiro Oikawa
Neoadjuvant endocrine therapy for estrogen receptor-positive primary breast cancer
Yutaka Yamamoto, Lisa Goto-Yamaguchi, Masako Takeno, Mutsuko Yamamoto-Ibusuki
Clinical imaging for the prediction of neoadjuvant chemotherapy response in breast cancer
Mitsuhiro Hayashi, Yutaka Yamamoto, Hirotaka Iwase
Neoadjuvant treatment for HER2-positive breast cancer
Masahiro Takada, Masakazu Toi
Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer
Makoto Kubo
Local management after neoadjuvant treatment for breast cancer
Takehiko Sakai, Takayuki Ueno
Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer
Takayuki Ueno

Original Article

Central nervous system cancers in the Middle East and North Africa (MENA) region: where does Lebanon stand
Hamza A. Salhab, Hussein H. Khachfe, Mohamad Y. Fares, Yazid Belkacemi, Hassan Hosseini

Review Article

Review on gall bladder myeloid sarcoma: a great masquerader
Kamal Kant Sahu, Santosh Rajaram Kale, Ahmad Daniyal Siddiqui

Disclosure:

1. The series “Neoadjuvant/adjuvant Treatment for Early Breast Cancer” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Yutaka Yamamoto and Takayuki Ueno served as the unpaid Guest Editors for the series.